

NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

Request for Insured Coverage of Alirocumab (Praluent), Evolocumab (Repatha)

PATIENT INFORMATION			
SURNAME	GIVEN NAME	HEALTH CARD NUMBER	DATE OF BIRTH
PATIENT ADDRESS			
DIAGNOSTIC INFORMATION- INITIAL REQUEST FOR COVERAGE			
Request for coverage of : <input type="checkbox"/> Alirocumab (Praluent) <input type="checkbox"/> Evolocumab (Repatha)			
<p>▶ Definite HeFH or Probable HeFH using <input type="checkbox"/> Simon Broome <input type="checkbox"/> Dutch Lipid Network <input type="checkbox"/> Genetic testing</p> <p><input type="checkbox"/> Patient is unable to reach LDL-C target (less than 2.0mmol/L or at least 50% reduction in LCL-C from untreated baseline) despite at least 3 months of continuous treatment with: High-dose statin (e.g., atorvastatin 80 mg, rosuvastatin 40mg) in combination with ezetimibe OR ezetimibe alone if high dose statin not possible due to rhabdomyolysis, contraindication or intolerance</p> <p>▶ Details of statin therapy (drug, dose, duration): _____</p> <p>▶ Details of ezetimibe therapy (duration): _____</p> <p>▶ LDL-C level prior to Praluent or Repatha, including date: _____</p> <p>▶ Start date of Praluent or Repatha, if applicable: _____</p>			
<p>For patients with intolerance to high dose statin or who cannot take a statin or ezetimibe due to an intolerance or contraindication the details must be provided as per published criteria.</p> <p><input type="checkbox"/> Documented myopathy or abnormal biomarkers (i.e. creatinine kinase greater than 5 times the upper limit of normal) with:</p> <p style="margin-left: 20px;"><input type="checkbox"/> Trial of at least two statins and dose reduction was attempted, intolerance was reversible upon statin discontinuation, but reoccurred with statin re-challenge where clinically appropriate and one statin initiated at the lowest daily starting dose AND</p> <p style="margin-left: 20px;"><input type="checkbox"/> Other known causes of intolerance or abnormal biomarkers have been ruled out</p> <p>Details of statin and ezetimibe therapy:</p>			
REQUESTS FOR RENEWAL			
▶ LDL-C level: _____ Date: _____			
PRESCRIBER NAME & ADDRESS:		<p>_____</p> <p style="text-align: center;">PRESCRIBER SIGNATURE</p>	
<p style="text-align: center;">_____</p> <p style="text-align: center;">LICENCE #</p>		<p style="text-align: center;">_____</p> <p style="text-align: center;">DATE</p>	

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please Return Form To: Nova Scotia Pharmacare Programs
P.O. Box 500, Halifax, NS B3J 2S1
Fax: (902) 496-4440